ЕКСПРЕСІЯ ГЕНІВ, ЗАЛУЧЕНИХ ДО РЕГУЛЯЦІЇ ШЛЯХУ р53, ПРИ НЕЙРОБЛАСТОМІ: СТИСЛИЙ ОГЛЯД
DOI:
https://doi.org/10.32471/exp-oncology.2312-8852.vol-44-no-4.18960Ключові слова:
нейробластома, сигнальний шлях р53, експресія генів, мікроРНКАнотація
Пошук нових прогностичних генетичних та епігенетичних маркерів та маркерів стратифікації у хворих на нейробластому є нагальною проблемою педіатричної онкології. В огляді узагальнено досягнутий на сьогодні прогрес у вивченні експресії генів, задіяних у регуляції шляху передачі сигналу за участю р53 в клітинах нейробластоми. Розглянуто декілька маркерів, асоційованих з ризиком рецидиву та несприятливим прогнозом. Серед них ампліфікація MYCN, високий рівень експресії MDM2 та GSTP1, гомозиготність за мутантним варіантом гена GSTP1 (A313G-поліморфізм). Розглянуто також прогностичні критерії нейробластоми, що базуються на аналізі експресії miR-34a, miR-137, miR-380-5p, та miR-885-5p, які залучені до регуляції шляхів, опосередкованих р53. Представлено власні дані авторів щодо ролі всіх зазначених маркерів у регуляції шляху пере¬дачі сигналу за участю р53 в клітинах нейробластоми. Вивчення змін експресії мікроРНКта генів, залучених до регуляції шляхів, опосередкованих р53, не тільки поглиблює розуміння механізмів патогенезу нейробластоми, а й може обґрунтувати нові підходи для визначення груп ризику та стратифікації за ризиком хворих на нейробластому, що буде сприяти оптимізації лікування, виходячи з генетичних характеристик пухлини.
Посилання
Maris JM, Hogarty MD, Bagatell R, et al. Neuroblastoma. Lancet 2007; 369: 2106–20. doi: https://doi.org/10.1016/S0140-6736(07)60983-0
Huang M, Weiss WA. Neuroblastoma and mycn. Cold Spring Harb Perspect Med 2013; 3: a015669. doi: https://doi.org/10.1101/cshperspect.a015669
Bagatell R, Beck-Popovic M, London WB, et al. Significance of mycn amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the international neuroblastoma risk group database. J Clin Oncol 2009; 27: 365–70. doi: https://doi.org/10.1200/JCO.2008.17.9184
Canete A, Gerrard M., Rubie H, et al. Poor survival for infants with mycn-amprified metastatic neuroblastoma despite intensified treatment: the international society of paediatric oncology european neuroblastoma experience. J Clin Oncol 2009; 27: 1014–9. doi: https://doi.org/10.1200/JCO.2007.14.5839.
Bai L, Zhu W. P53 : structure, function and therapeutic applications. J Cancer Mol 2006; 2: 141–53. doi: 10.29685/JCM.200608.0002
Tweddle DA, Pearson AD, Haber M, et al. The p53 pathway and its inactivation in neuroblastoma. Cancer Lett 2003; 197: 93–8. doi: https://doi.org/10.1016/s0304-3835(03)00088-0.
Barone G, Tweddle D, Shohet JM, et al. MDM2-p53 interaction in paediatric solid tumours: preclinical rationale, biomarkers and resistance. Current Drug Targets 2014; 15: 114–23. PMID: 24387312.
Chen L, Iraci N, Gherardi S, et al. P53 is a direct transcriptional target of mycn in neuroblastoma. Cancer Res 2010; 70: 1377–88. doi: https://doi.org/10.1158/0008-5472
Zhi F, Wang R, Wang Q, et al. MicroRNAs in neuroblastoma: small-sized players with a large impact. Neurochem Res 2014; 39: 613–23. doi: https://doi.org/10.1007/s11064-014-1247-9
Stallings RL. MicroRNA involvement in the pathogenesis of neuroblastoma: potential for microrna mediated therapeutics. Curr Pharm Des 2009; 15: 456–62. doi: https://doi.org/10.2174/138161209787315837
Mei H, Lin ZY, Tong QS. The roles of micrornas in neuroblastoma. World J Pediatr 2014; 10: 10–6. doi: https://doi.org/10.1007/s12519-014-0448-2
Welch C, Chen Y, Stallings RL. MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene 2007; 26: 5017–50. doi: https://doi.org/10.1038/sj.onc.1210293
Cole K, Attiyeh EF, Mosse YP, et al. A functional screen identifies mir-34a as a candidate neuroblastoma tumor suppressor gene. Mol Cancer Res 2008; 6: 735–42. doi: https://doi.org/10.1158/1541-7786
Swarbrick A, Woods SL, Shaw A, et al. MiR-380-5p represses p53 to control cellular survival and is associated with poor outcome in mycn-amplified neuroblastoma. Nat Med 2010; 16: 1134–40. doi: https://doi.org/10.1038/nm.2227
Afanasyeva E, Mestdagh P, Kumps C, et al. MicroRNA mir-885-5p targets cdk2 and mcm5, activates p53 and inhibits proliferation and survival. Cell Death Differ 2011; 18: 974–84. doi: 10.1038/cdd.2010.164
Althoff K, Beckers A, Odersky A, et al. MiR-137 functions as a tumor suppressor in neuroblastoma by downregulating kdm1a. Int J Cancer 2013; 133: 1064–73. doi: https://doi.org/10.1002/ijc.28091
Pugh TJ, Morozova O, Attiyeh EF, et al. The genetic landscape of high-risk neuroblastoma. Nat Genet 2013; 45: 279–84. doi: https://doi.org/10.1038/ng.2529
Raggi CC, Bagnoni ML, Tonini GP, et al. Real-time quantitative pcr for the measurement of mycn amplification in human neuroblastoma with the taqman detection system. Clin Chem 1999; 45: 1918–24.
Inomistova MV, Svergun NM, Khranovska NM, et al. Prognostic significance of mdm2 gene expression in childhood neuroblastoma. Exp Oncol 2015; 37: 111–5.
Pontén F, Jirström K, Uhlen M. The human protein atlas — a tool for pathology. J Pathol 2008; 216: 387–93. doi: https://doi.org/10.1002/path.2440
Uhlen M, Fagerberg L, Hallstrom BM, et al. Tissue-based map of the human proteome. Science 2015; 347: 1260419. doi: https://doi.org/10.1126/science.1260419
Uhlen M, Oksvold P, Fagerberg L, et al. Towards a knowledge-based human protein atlas. Nat Biotechnol 2010; 28: 1248–50. doi: https://doi.org/10.1038/nbt1210-1248
Mooneya MR, Kortac DJ, Bachmanna AS. Anti-tumor effect of sulfasalazine in neuroblastoma. Biochem Pharmacol 2019; 162: 237–49. https://doi.org/10.1016/j.bcp.2019.01.007
Carr-Wilkinson J. High frequency of p53/mdm2/p14arf pathway abnormalities in relapsed neuroblastoma. Clin Cancer Res 2010; 16: 1108–18. doi: https://doi.org/10.1158/1078-0432.CCR-09-1865
Maerken T, Vandesompele J, Rihani А, et al. Escape from p53-mediated tumor surveillance in neuroblastoma: switching off the p14(arf)-mdm2-p53 axis. Cell Death Differ 2009; 16: 1563–72. doi: https://doi.org/10.1038/cdd.2009.138
Xue C, Haber M, Flemming C, et al. P53 determines multidrug sensitivity of childhood neuroblastoma. Cancer Res 2007; 67: 10351–60. doi: https://doi.org/10.1158/0008-5472
Rayburn E, Zhang R, He J, et al. MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr Cancer Drug Targets 2005; 5: 27–41. doi: https://doi.org/10.2174/1568009053332636
Zhao Y, Yu H, Hu W. The regulation of mdm2 oncogene and its impact on human cancers. Acta Biochim Biophys Sin (Shanghai) 2014; 46: 180–9. doi: https://doi.org/10.1093/abbs/gmt147
Sciot R. MDM2 amplified sarcomas: A literature review. Diagnostics (Basel) 2021; 11: 496. doi: https://doi.org/10.3390/diagnostics11030496
Reifenberger G, Liu L, Ichimura K, et al. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 1993; 53: 2736–9.
Schmidt MK, Reincke S, Broeks A, et al. Do mdm2 snp309 and tp53 r72p interact in breast cancer susceptibility? a large pooled series from the breast cancer association consortium. Cancer Res 2007; 67: 9584–90. doi: https://doi.org/10.1158/0008-5472
Yu Q, Li Y, Mu K, et al. Amplification of mdmx and overexpression of mdm2 contribute to mammary carcinogenesis by substituting for p53 mutations. Diagn Pathol 2014; 9: 71. doi: https://doi.org/10.1186/1746-1596-9-71
Slack A, Lozano G, Shohet JM. MDM2 as MYCN transcriptional target: implications for neuroblastoma pathogenesis. Cancer Lett 2005; 228: 21–7. doi: https://doi.org/10.1016/j.canlet.2005.01.050.
Zhang H, Gu L, Li J, et al. MDM2 regulates MYCN mRNA stabilization and translation in human neuroblastoma cells. Oncogene 2012; 31: 1342–53. doi: https://doi.org/10.1038/onc.2011.343
Brooks CL, Gu W. New insights into p53 activation. Cell Res 2010; 20: 614–21. doi: https://doi.org/10.1038/cr.2010.53
Barbieri E, De Preter K, Capasso M, et al. A p53 drug response signature identifies prognostic genes in high-risk neuroblastoma. PLoS One 2013; 8: e79843. doi: https://doi.org/10.1371/journal.pone.0079843
Gumy-Pause F, Pardo B, Khoshbeen-Boudal M, et al. GSTP1 hypermethylation is associated with reduced protein expression, aggressive disease and prognosis in neuroblastoma. Genes Chromosomes Cancer 2012; 51: 174–85. doi: https://doi.org/10.1002/gcc.20941
Townsend DM, Tew KD. The role of glutathione-s-transferase in anti-cancer drug resistance. Oncogene 2003; 22: 7369-75. doi: 10.1038/sj.onc.1206940
Zhang BL, Sun T, Zhang BN, et al. Polymorphisms of gstp1 is associated with differences of chemotherapy response and toxicity in breast cancer. Chin Med J (Engl) 2011; 124: 199–204.
Hayes JD, Flanagan JU, Jowsey IR. Glutathione transferases. Annu Rev Pharmacol Toxicol 2005; 45: 51–88. doi: https://doi.org/10.1146/annurev.pharmtox.45.120403.095857
Lo H-W, Stephenson L, Cao X, et al. Identification and functional characterization of the human glutathione s-transferase p1 gene as a novel transcriptional target of the p53 tumor suppressor gene. Mol Cancer Res 2008; 6: 843–50. doi: https://doi.org/10.1158/1541-7786
Rothenberg AB, Berdon WE, D’Angio GJ, et al. Neuroblastoma—remembering the three physicians who described it a century ago: James Homer Wright, William Pepper and Robert Hutchison. Pediatr Radiol 2009; 39: 155–60. doi: https://doi.org/10.1007/s00247-008-1062-z
Ben Salah G, Kallabi F, Maatoug S, et al. Polymorphisms of glutathione s-transferases m1, t1, p1 and a1 genes in the tunisian population: an intra and interethnic comparative approach. Gene 2012; 498: 317–22. doi: https://doi.org/10.1016/j.gene.2012.01.054
Fletcher JI, Gherardi S, Murray J, et al. N-Myc regulates expression of the detoxifying enzyme glutathione transferase GSTP1, a marker of poor outcome in neuroblastoma. Cancer Res 2012; 72: 845–53. doi: https://doi.org/10.1158/0008-5472.CAN-11-1885
Bellincampi L, Ballerini S, Bernardini S, et al. Glutathione transferase p1 polymorphism in neuroblastoma studied by endonuclease restriction mapping. Clin Chem Lab Med 2001; 39: 830–5. doi: https://doi.org/10.1515/CCLM.2001.138
Lanciotti M, Coco S, Di Michele P, et al. Glutathione s-transferase polymorphisms and susceptibility to neuroblastoma. Pharmacogenet Genomics 2005; 15: 423-6. doi: https://doi.org/10.1097/01213011-200506000-00008
Inomistova M, Khranovskaya NM, Skachkova OV, et al. GSTP1 gene expression and a313g polymorphism can affect neuroblastoma outcome. Pediatric Blood & Cancer 2017; 64: S230. https://doi.org/10.1002/pbc.26772
Hamilton M, Rajapakshe K, Hartig SM, et al. Identification of a pan-cancer oncogenic microrna superfamily anchored by a central core seed motif. Nat Commun 2013; 4: 2730. doi: https://doi.org/10.1038/ncomms3730
He L, He X, Lim LP, et al. A microrna component of the p53 tumour suppressor network. Nature 2007; 447: 1130–4. doi: https://doi.org/10.1038/nature05939
Hébert SS, De Strooper B. Molecular biology. miRNAs in neurodegeneration. Science 2007; 317: 1179–80. doi: https://doi.org/10.1126/science.1148530
Schulte JH, Schowe B, Mestdagh P, et al. Accurate prediction of neuroblastoma outcome based on miRNA expression profiles. Int J Cancer 2010; 127: 2374–85. doi: https://doi.org/10.1002/ijc.25436
Garzon R, Calin GA, Croce CM. MicroRNAs in cancer. Annu Rev Med 2009; 60: 167–79. doi: https://doi.org/10.1146/annurev. med.59.053006.104707
Lodygin D, Tarasov V, Epanchintsev A, et al. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 2008; 7: 2591–600. doi: https://doi.org/10.4161/cc.7.16.6533.
De Antonellis P, Carotenuto M, Vandenbussche J, et al. Early targets of mir-34a in neuroblastoma. Mol Cell Proteomics 2014; 13: 2114–31. doi: https://doi.org/10.1074/mcp.M113.035808
Inomistova MV, Khranovska NM, Skachkova OV, et al. MicroRNA mir-34 family expression and clinical outcome of neuroblastoma. Studia Biol 2016; 10: 5–14.
Smrt RD, Szulwach KE, Pfeiffer RL, et al. MicroRNA mir-137 regulates neuronal maturation by targeting ubiquitin ligase mind bomb-1. Stem Cells 2010; 28: 1060–70. doi: https://doi.org/10.1002/stem.431
Shi Y, Zhao X, Hsieh J, et al. MicroRNA regulation of neural stem cells and neurogenesis. J Neurosci 2010; 30: 14931–96. doi: https://doi.org/10.1523/JNEUROSCI.4280-10.2010
Althoff K, Beckers A, Odersky A, et al. MiR-137 functions as a tumor suppressor in neuroblastoma by downregulating KDM1a. Int J Cancer 2013; 133: 1064–73. doi: https://doi.org/10.1002/ijc.28091
Neault M, Mallette FA, Richard S. MiR-137 modulates a tumor suppressor network-inducing senescence in pancreatic cancer cells. Cell Rep 2016; 14: 1966–78. doi: https://doi.org/10.1016/j.celrep.2016.01.068
Inomistova MV, Khranovska NM, Skachkova OV, et al. MiR-137 expression in neuroblastoma: a role in clinical course and outcome. Biopol Cell 2016; 32: 222–8. doi: https://doi.org/10.7124/bc.000924
Inomistova MV, Khranovska NM, Skachkova OV, et al. Alteration of mir-380-5p exspression in neuroblastoma. Visnyk problem biologii’ i medycyny 2016; 3: 162–6.
Swarbrick A, Woods SL, Shaw A. Mir-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN amplified neuroblastoma. Nat Med 2010; 16: 1134–40. doi: https://doi.org/10.1038/nm.2227
Gui J, Tian Y, Wen X, et al. Serum microrna characterization identifies mir-885-5p as a potential marker for detecting liver pathologies. Clin Sci (Lond) 2011; 120: 183–93. doi: https://doi.org/10.1042/CS20100297
Inomistova M, Khranovska N, Skachkova O, et al. Significance of mir-885-5p in neuroblastoma outcome. Biol Stud 2015; 9: 23–30. doi: https://doi.org/10.30970/sbi.0903.450
##submission.downloads##
Опубліковано
Як цитувати
Номер
Розділ
Ліцензія
Авторське право (c) 2023 Експериментальна онкологія
Ця робота ліцензується відповідно до Creative Commons Attribution-NonCommercial 4.0 International License.
